DocGo (DCGO) Q1 2026: SteadyMD Run Rate Hits $36M, Driving Virtual Care Surge
SteadyMD’s rapid ascent is reshaping DocGo’s revenue mix, with virtual care and in-home services now outpacing legacy growth. Margin headwinds from labor and fuel costs muted bottom-line improvement, but operational integration and cost cuts are set to accelerate in the second half. Investors should monitor working capital pressure and the pace of payer contract expansion as DocGo transitions to a multi-modal care platform.
Summary
- Virtual Care Integration: SteadyMD’s momentum is fueling DocGo’s shift to a more diversified, tech-enabled care model.
- Margin Constraints Persist: Labor incentives and fuel costs are offsetting revenue outperformance, delaying EBITDA improvement.
- Operational Leverage Watch: Cost-cutting and clinical hiring gains must deliver in H2 to realize profitability targets.
Business Overview
DocGo is a mobile health services provider that delivers medical transportation, virtual care, and in-home clinical services. The company generates revenue through two main segments: medical transportation (non-emergency and specialty patient transport, primarily for hospital systems) and mobile health (including remote patient monitoring, care gap closure, mobile phlebotomy, and the SteadyMD virtual care platform). DocGo’s business model leverages technology and a distributed clinical workforce to serve payers, providers, and digital health partners, with a growing emphasis on “care anywhere” delivery.
Performance Analysis
DocGo’s Q1 results highlight a business in transition, with legacy revenue declines from the wind-down of migrant projects more than offset by robust growth in core offerings. Excluding one-time migrant revenues, underlying revenue increased 24% year over year, led by SteadyMD’s $9.5 million contribution and record-high medical transportation volumes. The mobile health segment posted a 38% YoY increase (ex-SteadyMD), with remote patient monitoring and care gap closure driving dollar growth and margin improvement.
However, profitability lagged top-line gains. Adjusted EBITDA loss widened due to higher labor incentives for SteadyMD clinicians and a spike in fuel costs, which jointly compressed gross margin by nearly a full percentage point. While cost-cutting initiatives began to show in Q1, their full impact is not expected until Q3. Cash flow was pressured by delayed collections from New York City contracts, though $8 million was received in early Q2, partially alleviating near-term liquidity concerns. Management raised full-year revenue guidance but left EBITDA targets unchanged, reflecting a cautious view on margin recovery.
- SteadyMD Outperformance: Virtual care volumes and new contracts pushed SteadyMD to a $36 million annualized run rate, exceeding initial projections.
- Medical Transport Record: Segment revenue hit an all-time high, with strong demand in New York and expansion into new markets.
- Margin Drag Factors: Labor incentives, clinical hiring lag, and fuel inflation offset gains from business mix and cost controls.
DocGo’s shift toward recurring, technology-enabled care is accelerating, but execution risk remains as the company works through integration, cost discipline, and working capital normalization.
Executive Commentary
"A major driver of our strong revenue performance and increased revenue guidance is our virtual care offering, SteadyMD. We noted this upward trend in our last earnings call, and we are pleased to share that this trend has accelerated."
Lee Beanstalk, Chief Executive Officer
"The year-over-year revenue decline was entirely due to the wind-down of migrant-related projects. Removing migrant-related revenues, we saw a revenue increase of 24% year-over-year in Q1."
Norm, Chief Financial Officer
Strategic Positioning
1. Virtual Care as Core Growth Engine
SteadyMD, virtual care platform, is now central to DocGo’s growth narrative. Its $9.5 million Q1 performance, new contracts with online pharmacies, and expansion into weight loss and wellness prescriptions demonstrate diversification beyond legacy transport. Integration with in-home visits and partnerships with digital health and wearable companies position DocGo for long-term relevance in hybrid care delivery.
2. In-Home and Mobile Health Expansion
Mobile phlebotomy, care gap closure, and remote monitoring are scaling rapidly. Mobile phlebotomy is projected to grow 75% in 2026, with daily visits targeted to rise from 600 to 900. The care gap closure business now serves over 1.6 million lives, and remote patient monitoring reached $4.1 million in Q1 revenue at >50% margin, supporting blended margin improvement as the mix shifts toward higher-value services.
3. Operational Integration and Cost Discipline
Recruiting and cost-cutting are key levers for 2026. SteadyMD’s hiring blitz increased clinical headcount 45% to meet demand, while SG&A reductions are expected to accelerate through Q2 and Q3 as vendor contracts roll off and workforce streamlining takes effect. Management expects sequential declines in operating expenses, with the full benefit realized by Q3.
4. Medical Transportation Stability
Contract renewals and geographic expansion in medical transport provide revenue durability. New wins in New York, Tennessee, Wisconsin, and the UK, plus record segment revenue, demonstrate continued demand, though fuel price volatility and lack of indexed cost pass-through remain margin risks.
5. Strategic Alternatives Process
Ongoing evaluation of strategic alternatives could reshape DocGo’s capital structure or ownership. While management provided little detail, the process introduces uncertainty but also potential upside if asset value is unlocked or new partners accelerate growth.
Key Considerations
DocGo’s Q1 marks an inflection point as virtual and in-home care move to the fore, but margin and cash flow execution must be closely monitored. The company’s ability to scale technology-enabled services while managing cost and integration risk will determine its trajectory in 2026.
Key Considerations:
- Revenue Mix Shift: Virtual care and in-home services now comprise a larger share, reducing reliance on lower-growth legacy segments.
- Margin Sensitivity: Labor and fuel costs can quickly erode profitability, especially with limited contractual cost pass-through.
- Working Capital Pressure: Delays in receivables collection create near-term liquidity risk, though recent inflows offer partial relief.
- Cost Discipline Execution: SG&A reductions are lagging but expected to accelerate, with full impact not seen until Q3.
- Payer Pipeline: Success in signing new payers and expanding care gap contracts will be key to sustaining mobile health momentum.
Risks
Margin recovery is not guaranteed as DocGo faces persistent labor and fuel cost headwinds, with most contracts lacking indexed cost adjustment. Working capital strain from delayed government receivables could intensify if collections slow further. Integration risk remains high as SteadyMD and mobile health operations scale, and any slowdown in payer adoption or contract wins could undercut the revenue trajectory. The ongoing strategic alternatives process adds a layer of uncertainty for investors.
Forward Outlook
For Q2 2026, DocGo expects:
- Continued revenue growth in SteadyMD and mobile health, with margin improvement as hiring and technology integration ramp.
- Operating expenses to decline sequentially as cost cuts and vendor transitions take hold.
For full-year 2026, management raised revenue guidance to $300–315 million (from $290–310 million) but maintained adjusted EBITDA loss guidance at $5–10 million. Drivers for the year include:
- SteadyMD run rate of $35–36 million, with upside from new contracts and customer onboarding.
- Medical transportation segment revenue of $210–215 million, anchored by recent renewals and UK expansion.
Management emphasized that margin gains are expected in the second half as cost initiatives and clinical hiring fully flow through the P&L, but near-term working capital and fuel price volatility will persist.
Takeaways
DocGo’s transformation to a tech-enabled, multi-modal care provider is gaining traction, but the margin recovery story remains unfinished.
- Virtual Care Scale: SteadyMD’s outperformance is broadening DocGo’s addressable market and deepening integration with in-home services.
- Margin and Cash Flow Watch: Cost discipline and timely collections are critical to achieving second-half profitability and funding growth.
- Payer and Provider Expansion: Tracking new contract wins and care gap pipeline execution will be key to sustaining above-market growth rates.
Conclusion
DocGo’s Q1 2026 underscores the promise and challenge of scaling hybrid healthcare delivery. Revenue momentum is robust, but margin and execution risks remain front and center. The next two quarters will be decisive for validating the company’s ability to deliver sustainable profitability as it pivots to a more diversified, technology-driven model.
Industry Read-Through
DocGo’s results signal accelerating demand for virtual and in-home care, with integration of telehealth and mobile services emerging as a competitive advantage. The company’s experience highlights both the margin risks of labor and fuel volatility and the upside of payer-driven care gap closure models. For the broader healthcare services sector, technology-enabled care delivery and payer partnerships will be key growth drivers, but cost discipline and working capital management are essential as reimbursement models evolve. Competitors and partners should watch for further consolidation and platform integration as virtual and physical care converge.